DrugApr 8, 2026
K.C. Pharmaceuticals STERILE EYE DROPS SOOTHING TEARS recall — FDA D-0415-2026
Lack of Assurance of Sterility
Class IIFDA: OngoingK.C. Pharmaceuticals, Inc
10,685drug recall records
953FDA Class I records
8firms with 5+ records
Aidapak Services, LLC537 records
Database records
Records — page 12
10,685 detailed records are currently available in this category.
DrugApr 1, 2026
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg recall — FDA D-0405-2026
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 1, 2026
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg recall — FDA D-0404-2026
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 1, 2026
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg recall — FDA D-0406-2026
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc
DrugApr 1, 2026
SODIUM IODIDE I-131 Gelatin Capsule Pack for use with the Sodium Iodide I-131 Kit recall — FDA D-0401-2026
Failed Tablet/Capsule Specifications
Class IIIFDA: OngoingRadnostix
DrugMar 25, 2026
IBUPROFEN Children's Ibuprofen Oral Suspension, USP, 100 mg per 5mL, 4 FL OZ (120 mL) bottle recall — FDA D-0390-2026
Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product.
Class IIFDA: OngoingSTRIDES PHARMA INC
DrugMar 25, 2026
Pitavastatin Tablets, 2 mg recall — FDA D-0391-2026
Presence of foreign tablets/capsules: one Pitavastatin tablet 1mg found in bottle of Pitavastatin tablets 2mg
Class IIIFDA: OngoingAnnora Pharma Private Limited
DrugMar 25, 2026
Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL, (10 mg/mL), 10x10 mL Multiple recall — FDA D-0398-2026
Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities:…
Class IIFDA: OngoingSOMERSET THERAPEUTICS LLC
DrugMar 18, 2026
Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle recall — FDA D-0400-2026
Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.
Class IIFDA: OngoingZydus Pharmaceuticals (USA) Inc
DrugMar 11, 2026
Nilotinib Capsules, 150 mg per capsule recall — FDA D-0381-2026
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Class IIIFDA: OngoingCipla USA, Inc.
DrugMar 11, 2026
Harbin Jixianglong Biotech Co Semaglutide, For Rx compounding use only recall — FDA D-0380-2026
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Class IIFDA: OngoingHarbin Jixianglong Biotech Co., Ltd.
DrugMar 11, 2026
TEMOZOLOMIDE Product label: Temozolomide Capsules, 5mg recall — FDA D-0384-2026
Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
Class IIFDA: OngoingRising Pharma Holding, Inc.
DrugMar 11, 2026
Harbin Jixianglong Biotech Co Semaglutide, For Rx compounding use only recall — FDA D-0379-2026
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Class IIFDA: OngoingHarbin Jixianglong Biotech Co., Ltd.
DrugMar 11, 2026
Nilotinib Capsules, 200 mg per capsule recall — FDA D-0382-2026
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Class IIIFDA: OngoingCipla USA, Inc.
DrugMar 11, 2026
Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC recall — FDA D-0389-2026
Presence of Particulate Matter: Due to production issues
Class IIFDA: OngoingRadnostix
DrugMar 11, 2026
ACME UNITED 1) BZK Antiseptic Towelettes recall — FDA D-0362-2026
CGMP Deviations
Class IIFDA: OngoingACME UNITED CORPORATION
DrugMar 4, 2026
Wizcure Pharmaa Private BioGlo Fluorescein Sodium Ophthalmic Strips USP, 100 diagnostic recall — FDA D-0352-2026
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Class IIFDA: OngoingWizcure Pharmaa Private Limited
DrugMar 4, 2026
Wizcure Pharmaa Private Bio Glo Fluorescein Sodium Ophthalmic Strips USP, 300 diagnostic recall — FDA D-0351-2026
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Class IIFDA: OngoingWizcure Pharmaa Private Limited
DrugMar 4, 2026
Wizcure Pharmaa Private Vista Tears Polyethylene Glycol 400 0.4% w/v, Propylene Glycol 0.3% recall — FDA D-0346-2026
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Class IIFDA: OngoingWizcure Pharmaa Private Limited
DrugMar 4, 2026
Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1x100 mL recall — FDA D-0343-2026
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial…
Class IIIFDA: OngoingSlate Run Pharmaceuticals
DrugMar 4, 2026
Amantadine HCl, Capsules, UPS, 100 mg, 50 Capsules (5 x 10) unit dose recall — FDA D-0341-2026
Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
Class IIFDA: OngoingAvKARE
DrugMar 4, 2026
Vista Gel Hypromellose USP 0.3% w/v, Eye Drops Dry Eye Relief Lubricating Gel, 10 ml. recall — FDA D-0347-2026
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Class IIFDA: OngoingWizcure Pharmaa Private Limited
DrugMar 4, 2026
ADBRY recall — FDA D-0339-2026
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Class IIFDA: OngoingLEO PHARMA INC
DrugMar 4, 2026
Vista Gonio Eye Lubricant, Hypromellose Ophthalmic Solution USP recall — FDA D-0349-2026
Lack of Assurance of Sterility: Products have not been manufactured in conformance with current good manufacturing practices.
Class IIFDA: OngoingWizcure Pharmaa Private Limited
How to use this drug recall index
A drug recall record can include the reason for recall, firm, status, distribution pattern, quantity and FDA classification. This site does not provide medical advice; it organizes public recall information and links users back to official sources.
Recall Lookup USA keeps the last complete source record available when an official data service is temporarily unavailable. When a source provides only a few fields, we show only those known facts rather than padding the page with generic text.
What the database can and cannot tell you
This database is designed for discovery and reference. It can help you locate a relevant recall record, identify the recalling firm or NHTSA campaign, compare dates and classifications, and follow the official source. It is not a substitute for a VIN-specific NHTSA check, a manufacturer notice, medical advice or instructions issued by the recalling company.